Our Pricing

Saxenda for Weight Loss: Clinical Evidence, Dosing, and UK Availability

Published on: June 03, 2026

Saxenda for weight loss is a once-daily injectable prescription medication containing liraglutide 3 mg, licensed by the MHRA for chronic weight management in adults with a BMI of 30 or above, or 27 or above with weight-related comorbidities. In clinical trials, patients using Saxenda for weight loss alongside lifestyle modification achieved an average weight reduction of 8% of initial body weight over 56 weeks, compared to 2.6% with placebo [1]. At Cured Pharmacy, Saxenda is available from £124.99 following a free online consultation with our UK-registered prescribers, ensuring safe, evidence-based treatment tailored to your individual health profile.

How Saxenda for Weight Loss Works in the Body

Saxenda for weight loss contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism. When administered subcutaneously, liraglutide binds to GLP-1 receptors in the brain's hypothalamus, reducing hunger signals and increasing feelings of fullness after meals [2]. This mechanism helps patients consume fewer calories without the constant sensation of deprivation that often undermines traditional dieting efforts.

Beyond appetite suppression, Saxenda for weight loss slows gastric emptying, meaning food remains in the stomach longer and prolongs satiety. Clinical pharmacology studies demonstrate that liraglutide also modulates insulin secretion in a glucose-dependent manner, which can improve glycaemic control in patients with prediabetes or type 2 diabetes [2]. The combined effect of reduced caloric intake and improved metabolic parameters makes Saxenda a comprehensive tool for weight management when used alongside a reduced-calorie diet and increased physical activity.

Clinical Trial Evidence for Saxenda for Weight Loss Outcomes

The efficacy of Saxenda for weight loss has been established through the SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence) clinical trial programme, which enrolled over 5,000 participants across multiple international sites. In the pivotal SCALE Obesity and Prediabetes trial, 63.2% of patients receiving liraglutide 3 mg achieved at least 5% weight loss at 56 weeks, compared to 27.1% in the placebo group [1]. More impressively, 33.1% of Saxenda-treated patients lost 10% or more of their initial body weight, a threshold associated with significant improvements in cardiovascular and metabolic risk factors.

Long-term data from the SCALE Maintenance trial demonstrated that Saxenda for weight loss helps preserve weight reduction achieved during an initial low-calorie diet phase. Participants who continued liraglutide after a run-in diet period maintained an average additional weight loss of 6.2% over 56 weeks, whereas those switched to placebo regained 0.2% [3]. These findings underscore that Saxenda is most effective as part of a sustained lifestyle modification programme rather than a short-term intervention.

Weight Loss Outcomes by Patient Subgroup

Subgroup analyses from the SCALE trials reveal that Saxenda for weight loss produces consistent results across diverse patient populations, including those with prediabetes, obstructive sleep apnoea, and polycystic ovary syndrome. Patients with higher baseline BMI (≥35 kg/m²) experienced greater absolute weight loss, though percentage reductions remained comparable to those with lower starting weights [1]. Importantly, the treatment demonstrated efficacy regardless of age, sex, or ethnicity, making it a versatile option for a broad spectrum of individuals struggling with obesity.

Dosing Schedule and Administration of Saxenda for Weight Loss

Saxenda for weight loss is initiated at a low dose of 0.6 mg once daily, administered subcutaneously in the abdomen, thigh, or upper arm. The dose is gradually escalated each week—to 1.2 mg, 1.8 mg, 2.4 mg, and finally the maintenance dose of 3 mg—to minimise gastrointestinal side effects such as nausea and vomiting [4]. This titration schedule allows the body to adapt to the medication's effects on gastric motility and appetite signalling, improving tolerability and adherence.

Each Saxenda pen contains 18 mg of liraglutide and delivers doses in 0.6 mg increments, providing a 6-day supply at the 3 mg maintenance dose. Patients are advised to inject at approximately the same time each day, independent of meals, to maintain stable plasma concentrations. If a dose is missed, it should be administered within 12 hours; otherwise, the missed dose should be skipped to avoid doubling up. Proper injection technique and site rotation are essential to prevent lipohypertrophy and ensure consistent absorption [4].

Storage and Handling Requirements

Unused Saxenda pens must be stored in a refrigerator at 2°C to 8°C and protected from light. Once in use, a pen may be kept at room temperature (below 30°C) or in the refrigerator for up to 30 days. Patients should never freeze Saxenda, and any pen that has been frozen must be discarded. The pen cap should be replaced after each injection to protect the medication from light and contamination, ensuring the liraglutide remains stable and effective throughout the usage period.

Common Side Effects and Management Strategies for Saxenda for Weight Loss

The most frequently reported side effects of Saxenda for weight loss are gastrointestinal in nature, including nausea, diarrhoea, constipation, vomiting, and abdominal discomfort. These symptoms are typically mild to moderate, occur most often during the dose-escalation phase, and tend to diminish over time as tolerance develops [4]. In clinical trials, nausea was reported by approximately 39% of liraglutide-treated patients, though only 4% discontinued treatment due to this adverse event [1].

To mitigate gastrointestinal side effects, patients using Saxenda for weight loss are advised to eat smaller, more frequent meals, avoid high-fat foods, and stay well hydrated. Slowing the rate of dose escalation—extending each step by an additional week if necessary—can also improve tolerability. Rare but serious adverse events include pancreatitis, gallbladder disease, and increased heart rate; patients should seek immediate medical attention if they experience severe abdominal pain, persistent tachycardia, or signs of acute pancreatitis [4]. Our clinical team at Cured Pharmacy provides ongoing support to help manage side effects and optimise treatment outcomes.

Who Is Suitable for Saxenda for Weight Loss Treatment

Saxenda for weight loss is licensed in the UK for adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea [4]. The medication is intended as an adjunct to a reduced-calorie diet and increased physical activity, not as monotherapy. Prescribers assess each patient's medical history, current medications, and weight loss goals during the online consultation to determine suitability and rule out contraindications.

Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as liraglutide has been associated with thyroid C-cell tumours in rodent studies [4]. It should not be used during pregnancy or breastfeeding, and caution is advised in patients with a history of pancreatitis, severe renal or hepatic impairment, or inflammatory bowel disease. At Cured Pharmacy, our UK-registered prescribers conduct a thorough clinical assessment to ensure Saxenda for weight loss is both safe and appropriate for your individual circumstances, subject to approval by a qualified healthcare professional.

Monitoring and Follow-Up During Treatment

Patients prescribed Saxenda for weight loss should be monitored regularly to assess treatment response, tolerability, and adherence. NICE guidance recommends discontinuing liraglutide if a patient has not achieved at least 5% weight loss after 12 weeks at the 3 mg maintenance dose, as continued use is unlikely to provide meaningful benefit [5]. Periodic review of blood pressure, heart rate, blood glucose, and lipid profiles helps identify improvements in cardiometabolic risk factors and guides ongoing management. Our team at Cured Pharmacy facilitates seamless follow-up consultations to support long-term success and adjust treatment plans as needed.

Pricing and Access to Saxenda for Weight Loss at Cured Pharmacy

At Cured Pharmacy, Saxenda for weight loss is available from £124.99 per pack, representing competitive UK pricing for this MHRA-licensed medication. New patients can Save £20 off their first order using the code Weightlossnew, reducing the initial cost to £124.99. All prices are displayed upfront before the online consultation, ensuring complete transparency with no hidden fees. Our pricing structure reflects our commitment to making evidence-based weight management treatments accessible to patients across the UK.

Ordering Saxenda for weight loss at Cured Pharmacy is straightforward: complete a free online clinical questionnaire reviewed by our UK-registered prescribers, receive a decision typically within hours, and have your medication dispatched in 100% discreet packaging with next-day delivery options. Every prescription is issued by a qualified healthcare professional registered with the General Pharmaceutical Council, ensuring compliance with UK regulations and the highest standards of patient safety. As superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, you can trust that your treatment is managed by experienced professionals dedicated to your health and wellbeing.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 13 August 2026]
2. Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3-14. [accessed 13 August 2026]
3. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451. [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2023). Saxenda 6 mg/ml solution for injection in pre-filled pen – Summary of Product Characteristics. Novo Nordisk Limited. [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2020). Obesity: identification, assessment and management (Clinical guideline CG189). [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.